|
|
Volumn 160, Issue 1, 2003, Pages 24-
|
|
Depression, III: Treatments
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMPA RECEPTOR AFFECTING AGENT;
ANTIDEPRESSANT AGENT;
LITHIUM;
PHOSPHODIESTERASE IV INHIBITOR;
UNCLASSIFIED DRUG;
VALPROIC ACID;
ARTICLE;
BIPOLAR DISORDER;
BRAIN SIZE;
DEPRESSION;
DRUG MECHANISM;
DRUG TARGETING;
ENZYME ACTIVATION;
GRAY MATTER;
HIPPOCAMPUS;
HUMAN;
MOOD DISORDER;
NERVE CELL PLASTICITY;
NERVE DEGENERATION;
NERVOUS SYSTEM DEVELOPMENT;
NEUROPROTECTION;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN PHOSPHORYLATION;
PSYCHIATRIC TREATMENT;
SIGNAL TRANSDUCTION;
TRANSCRIPTION REGULATION;
ANIMALS;
ANTIDEPRESSIVE AGENTS;
BIPOLAR DISORDER;
BRAIN;
BRAIN-DERIVED NEUROTROPHIC FACTOR;
DEPRESSIVE DISORDER;
HUMANS;
NEUROPROTECTIVE AGENTS;
PROTO-ONCOGENE PROTEINS C-BCL-2;
RATS;
SECOND MESSENGER SYSTEMS;
|
|
EID: 0037225796
PISSN: 0002953X
EISSN: None
Source Type: Journal
DOI: 10.1176/appi.ajp.160.1.24 Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|
